HPV Testing And Pap Test Market To Reach $9.33 Billion By 2030

HPV Testing And Pap Test Market Growth & Trends

The global HPV testing and Pap test market size is expected to reach USD 9.33 billion by 2030, growing at a CAGR of 11.8% from 2023 to 2030, according to a new study by Grand View Research, Inc. Technological advancements, an increasing number of cervical cancer screening programs, and a high incidence of HPV infection are some major factors expected to drive the growth of the market over the forecast period. The disease accounts for 6.6% of all female cancers and the mortality rate of cervical cancer in low-and-middle-income countries is much higher. The increase in disease prevalence has boosted the demand for diagnostic products, thereby enabling market growth.

As per the Globocan estimates, in 2020, around 604,127 new cases of cervix and uterine cancer were diagnosed globally, which led to around 341,831 deaths in the same year. According to the WHO, 99% of these cases are linked to HPV infection. The high incidence rate of cervical cancer coupled with the high mortality rate is expected to boost the demand for HPV infection testing to reduce the disease burden.

Increasing approval of novel testing solutions and services to upsurge screening rates is further anticipated to support growth. In April 2020, Roche received FDA approval for its Cobas HPV screening to be used on Cobas 6800/8800 Systems, a fully automated and high-throughput system. Moreover, regulatory bodies are recommending technologically advanced tests for screening. For instance, in September 2021, the WHO recommended DNA-based testing for human papillomavirus to prevent cervical cancer.

Initiatives undertaken by regulatory bodies in regions with high disease prevalence are anticipated to fuel market growth. For instance, the Go Further partnership to end AIDS and cervical cancer is an initiative that provides cervical cancer screening in African countries with a high prevalence of HIV. HIV-positive women are five times more likely to develop cervical cancer than other women. The initiative is a collaborative effort by UNAIDS, the Bush Institute, Merck, and the U.S. President’s Emergency Plan for AIDS Relief.

Some major market players include Abbott; QIAGEN; BD (Becton Dickinson & Company); Quest Diagnostics Incorporated; Hologic Inc.; F. Hoffmann-La Roche Ltd.; Femasys, Inc.; Arbor Vita Corporation; Oncohealth Corporation; and Seegene Inc. The HPV and Pap testing industry is highly fragmented with several local players.

 Request a free sample copy or view report summary: HPV Testing And Pap Test Market Report

HPV Testing and Pap Test Market Report Highlights

• By type, the Pap test segment accounted for the largest revenue share in 2022, owing to the widespread implementation of screening programs

• By technology, the other technologies segment dominated the HPV testing and Pap test industry and accounted for the largest revenue share in 2022

• By application, cervical cancer screening held the largest revenue share in 2022 and is expected to grow at a lucrative CAGR during the forecast period due to investments by market players in the field and a higher incidence rate of disease

• The consumables segment dominated the HPV testing and Pap test industry and accounted for the largest revenue share in 2022 owing to high usage

• Based on end-use, the hospitals & clinics segment dominated the HPV testing and Pap test industry in 2022 as they serve as primary care settings for the diagnosis and treatment of all diseases, including HPV infections

• Based on region, North America dominated the HPV testing and Pap test industry and held the largest revenue share in 2022, due to high awareness about early diagnosis, well-established screening guidelines, and favorable healthcare reimbursement scenarios are the factors driving the growth of the market in the region

HPV Testing and Pap Test Market Segmentation

Grand View Research has segmented the global HPV testing and Pap test market based on test type, application, technology, product, end-use, and region:

HPV Testing and Pap Test Type Outlook (Revenue, USD Million, 2018 - 2030)

• Pap Test

• HPV Test      

HPV Testing and Pap Test Application Outlook (Revenue, USD Million, 2018 - 2030)

• Cervical Cancer Screening

• Vaginal Cancer Screening

HPV Testing and Pap Test Product Outlook (Revenue, USD Million, 2018 - 2030)

• Instruments

• Consumables

• Services

HPV Testing and Pap Test Technology Outlook (Revenue, USD Million, 2018 - 2030)

• PCR

• Immunodiagnostics

• Other Technologies

HPV Testing and Pap Test End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals & Clinics

• Laboratories

• Others

HPV Testing and Pap Test Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa

  • Saudi Arabia

  • South Africa

  • UAE

  • Kuwait

List of Key Players in the HPV Testing and Pap Test Market

• Abbott

• QIAGEN

• BD

• Quest Diagnostics Incorporated

• Hologic, Inc.

• F. Hoffmann-La Roche Ltd

• Femasys Inc.

• Arbor Vita Corporation

• NURX Inc.

• Seegene Inc.

• Thermo Fisher Scientific Inc.

• bioMérieux